What is uFraction8?
Headquartered in Falkirk, Scotland, uFraction8 specializes in the development of advanced microfluidics-based filtration systems. Founded in 2017, the company provides a high-efficiency alternative to traditional downstream processing methods, such as centrifuges and standard membrane filters. By utilizing hydrodynamic phenomena, uFraction8 enables more scalable and energy-efficient biomanufacturing. This technology is essential for industries ranging from biopharmaceuticals to food production, where reducing operational costs and improving yield are paramount. The company's market position is defined by its ability to replace legacy hardware with modular, sustainable solutions that align with the modern requirements of the bio-economy.
How much funding has uFraction8 raised?
uFraction8 has raised a total of $7.7M across 2 funding rounds:
Other Financing Round
$3.4M
Other Financing Round
$4.3M
Other Financing Round (2022): $3.4M, investors not publicly disclosed
Other Financing Round (2025): $4.3M led by The University of Edinburgh, Thia Ventures, Foresight Group, Alwyn Capital, Old College Capital, and Scottish Enterprise
Key Investors in uFraction8
The University of Edinburgh
A prestigious higher education institution in Scotland renowned for its research excellence in molecular biology and global health challenges.
Thia Ventures
A fund management company specializing in the intersection of food, biotechnology, and health to drive sustainable industrial growth.
Foresight Group
A leading independent infrastructure and private equity investment manager with a long-standing history of supporting innovative growth companies.
What's next for uFraction8?
With the recent influx of capital, uFraction8 is well-positioned to scale its operations and expand its footprint within the biomanufacturing ecosystem. The strategic focus will likely shift toward increasing manufacturing capacity and deepening market penetration in the biopharmaceutical and food-tech sectors. By leveraging its unique intellectual property, the company aims to further optimize downstream processing workflows, effectively lowering the barrier to entry for large-scale bio-based production. Future milestones will likely involve strategic partnerships to integrate its filtration technology into existing industrial pipelines, thereby cementing its role as a critical infrastructure provider in the global biotechnology landscape.
See full uFraction8 company page
